Results 41 to 50 of about 192,841 (253)
Ophthalmology and Therapy, 2019 Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou +3 more
doaj +1 more source
Faricimab Treat-and-Extend for Diabetic Macular Edema
OphthalmologyPurpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T +2 more
openaire +3 more sources
Frontiers in Medicine, 2021 Objective: We report the tri-center 1-year outcomes of a treat-and-extend (T&E) regimen in four-week intervals with ranibizumab for diabetic macular edema (DME).Methods: In this retrospective study, all eyes received 3 monthly loading injections of 0.
Chun-Ting Lai +14 more
doaj +1 more source
Myasthenia Gravis with Membranous Nephropathy, Successfully Treated with Extended Total Thymectomy.
Internal Medicine, 2000 A 46-year-old woman showed proteinuria and hematuria after left blepharoptosis, and revealed a histopathology of membranous nephropathy (MN) at renal biopsy. She was diagnosed as having myasthenia gravis (MG) because of a positive edrophonium test and anti-acetylcholine receptor (AchR) antibodies in serum.
MATSUDA, Masayuki +5 more
openaire +3 more sources
Российский офтальмологический журнал, 2020 Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods.
S. V. Nedogoda +5 more
doaj +1 more source
BMC Ophthalmology, 2022 The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s ...
Cheng-Kuo Cheng +15 more
doaj +1 more source
A simulation tool for better management of retinal services
BMC Health Services Research, 2018 Background Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients require frequent and long-term
Eren Demir +3 more
doaj +1 more source
Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
Российский офтальмологический журнал, 2023 Purpose. To evaluate long-term results of anti-VEGF therapy performed in a modified “treat-and-extend” regimen in macular edema secondary to central retinal vein occlusion.Material and methods.
A. B. Galimova, V. U. Galimova
doaj +1 more source
Frontiers in Medicine, 2022 PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia +22 more
doaj +1 more source
Treat & extend versus PRN in AMD
Acta Ophthalmologica, 2016 SummaryBasically 3 different approaches to anti‐VEGF treatment in AMD are in clinical use, a fixed regimen using monthly or bi‐monthly injections (IVI), a PRN strategy and a Treat and Extend (T&E) regimen.T&E is a proactive and individualized anti‐VEGF treatment regimen. Basically IVI are performed monthly until stability is achieved.
openaire +1 more source